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This is the most comprehensive report in the 
English-language literature on nail unit BCC. 
Because a number of extensive reviews regarding 
carcinoma of the hand lack specific tumor loca­
tion,14’15 however, it is possible that other cases, 
not included here, exist. There is further difficulty 
in establishing the exact number of cases because 
the validity of the histopathologic diagnoses in 
several cases has been questioned by Mehregan.16 
Also notable but not included in the summary is a 
case report by Ashby17 of a basosquamous carci­
noma that clinically mimicked paronychia.
Treatment of BCC of the nail unit has ranged 
from radiation to amputation. The use of Mohs 
micrographic surgery in 87 cases of nail unit squa­
mous cell carcinoma11 documented this as an 
excellent approach for cutaneous carcinomas 
lacking bone involvement. That report noted that 
healing by second intention gave superb results. 
With emphasis on achieving a permanent cure 
while preserving function and cosmetic appear­
ance of the nail unit, Mohs micrographic 
surgery3,6»8,9 followed by second-intention heal­
ing should be regarded as the current treatment of 
choice for nail unit BCC. Full- or split-thickness 
skin grafting is an alternative to second-intention 
healing when more rapid wound coverage is 
desired and when the wound base is sufficiently 
vascular to support a graft. Functionally and cos­
metically, the results are essentially equivalent.
All reported cases of nail unit BCC have lacked 
classic clinical features, resulting in initial clinical 
misdiagnosis. The presentation often mimics such 
benign processes as chronic paronychia, chronic 
dermatitis, or onychomycosis. A unique presenta­
tion of longitudinal melanonychia was reported in
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one case.9 Bowen’s disease is a malignant mimic. 
We stress the need for biopsy of all nail unit
lesions atypical in appearance, course, or response
to therapy.
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Reliability of two methods to assess morphea: Skin scoring and the 
use of a durometer
Marieke M. B. Seyger, MD,a Frank H. J. van den Hoogen, MD, PhD,b Theo de Boo, MSc,c 
and Elke M. G. J. de Jong, MD, PhDa Nijmegen, The Netherlands
To monitor patients with morphea, determina­
tion of disease status, including induration and the 
extent of involvement, is necessary. The ideal 
assessment would be a clinical skin score (pliabil­
ity together with area o f  involvement) in combi-
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nation with a quickly performed objective method 
to assess thickness.
Several methods have been advocated but have 
never been validated.1"3 Objective measurements 
with ultrasonography,415 laser Doppler flow- 
metry,6 skin torsion,1 and serum type III procolla­
gen aminoterminal peptide7 have been described. 
Rodnan, Lipinski, and Luksick8 measured skin 
thickness and collagen content in biopsy speci­
mens. This method, however, has the disadvantage 
of being invasive, time-consuming, and unsuitable 
for patients with widespread morphea.
A device to measure skin hardness (the durom- 
eter) was first described by Falanga and Bucalo9 
and was found to be useful in the assessment of 
patients with systemic sclerosis when used as a 
comparative test.10 For morphea, however, the use 
of the durometer has not been described.
Clinical scores of skin involvement have been 
used extensively in the assessment of patients with 
systemic sclerosis.11"16 For morphea, clinical skin 
scores have been used in a few cases but have 
never been evaluated for their reliability.1'3,17"19 
An easy and quickly performed modified skin 
score (MSS) for systemic sclerosis has been 
described by Zachariae et al.20 This scoring sys­
tem has the advantage of dividing the body into 
only seven regions (rather than 17 to 26 regions as 
in previous methods).8’11’15’17 The MSS measures 
the degree of thickening and pliability in combi­
nation with area of involvement.
Neither the durometer nor the MSS has been 
used before in the assessment of morphea, and the 
interobserver and intraobserver variability of both 
methods have not been determined. In this study, 
these were investigated. The degree of agreement 
between the two methods was also calculated.
PATIENTS AND METHODS 
Patients
Thirteen consecutive patients with histologically 
confirmed morphea were included in this study. All 
patients were scored twice at a 1 -week interval by three 
independent observers with variable experience: a con­
sultant dermatologist, a consultant rheumatologist, and 
a resident in dermatology. Each observer first conduct­
ed the MSS as described by Zachariae et al.20 and then 
assessed skin hardness in the most indurated lesion in 
each of seven regions by means of the durometer.
Clinical score
The MSS is a clinical skin score in which the body
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is divided into seven regions (R): head and neck, trunk, 
arms, hands, fingers, legs, and feet. The degree of 
thickening and pliability (T) was assessed on a 0 to 3 
scale: 0, normal skin; 1, thickened skin; 2, decreased 
ability to pinch or move skin; and 3, skin that is unable 
to be pinched or moved (hidebound). The most affect­
ed part of the region determined the score. In addition, 
involvement in each area (A) was determined by esti­
mation and given the following counts: 0, no involve­
ment; 7, less than 33%; 2, 33% to 67%; and 3, more 
than 67%. The sum of the numeric units for thickening 
and the percentage of area surface involved is the MSS. 
Thus the MSS is £(T 4- A)R1_R7. The possible minimum 
score is 0, representing no affected skin, and the maxi­
mum score is 42, for extreme involvement in all 
areas.20
Durometer scores
The hardness of the lesions was examined by means 
of a handheld durometer (model 1600-00; Rex Gauge 
Co., Glenview, 111.) with an affixed weight of approxi­
mately 400 gm. In this way measurements were carried 
out with a constant weight that did not allow addition­
al pressure.9,10 The durometer is fitted with a calibrat­
ed gauge that registers linearly divided units on a scale 
from 0 to 100. The durometer readings were taken at 
the intersection of two imaginary lines drawn through 
the largest horizontal and vertical diameters of the most 
indurated lesion in each of the seven regions. Four con­
secutive readings were taken at the same site while the 
patients were lying flat, and contraction and muscle 
tension were avoided by putting a pillow under the 
extremities. The total durometer score is the sum of the 
means of the four determinations at each site.
Statistical analysis
The total durometer score (the sum of the means of 
all body sites) was used for statistical analysis. 
Observer agreement for both methods was analyzed by 
considering the total amount of variation present in the 
ratings and estimating the amount of variability from 
the patients (o2p), the amount from the repeating of the 
measurements (a2r), the amount from the observers 
(a20), and the amount from random error (o2e). In a 
reliable method, the interobserver variability (clinician 
variation) and the intraobserver variability (variation 
from repeated measurements) should be low, whereas 
the variability caused by diversity of patients should be 
high.
All variances mentioned were estimated with the 
maximum likelihood variance components estimation 
procedure of the SAS package (SAS Institute Inc., 
Cary, N.C.). Results for the various sources of variation 
are presented as the percentage of the total variance
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Table I. Percentage of total variance from 
observers, repetition, patients, and random error
Variance (% of total) MSS Durometer score
Variance from patients 80.0 93.9
Variance from observers 2.2 0.5
Variance from repetition 0 0
Variance from random error 17.8 5.6
(cf2 + o20 + G2r + o2e). For analysis of correlations 
between the MSS and the durometer scores, the 
Spearman correlation coefficient was used.
RESULTS
Thirteen patients (four men and nine women) 
participated in this study. Their mean age was 49.2 
(± 4.57 SEM) years; the youngest was 20 years
n
old and the oldest was 68 years old. The duration 
of morphea ranged from 9 months to 7 years, with 
a mean of 3.9 (± 0.8 SEM) years. The number of 
body sites affected ranged from one to four; the 
fingers, hands, and feet were not affected in any 
patient.
In the MSS, the percentage of variance from 
the patients was high, 80.0% (Table I). This means
that the amount of variation from the other vari­
ables (observers, repeated measurement, and ran­
dom error) was low. The interobserver variability, 
expressed as the percentage of variance from 
observers, was 2.2% (Table I). The intraobserver 
variability, which is the variation from repetition 
of measurements by the same observer, was esti­
mated to be 0 (Table I). The interobserver vari­
ability in the durometer score was only 0.5, and 
intraobserver variability was estimated as 0.
Correlations between the total MSS and the 
durometer score were approximately 0.5. If only 
the pliability scores in the MSS were correlated 
with the durometer scores, a correlation of more 
than 0.8 was found. The correlations between 
MSS (total MSS and pliability alone) and the 
durometer score for the different observers and 
both time points are summarized in Table II.
DISCUSSION
To assess disease activity and efficacy of thera­
py in scleroderma, it is important to use standard­
ized outcome measures that are reliable, clinically 
meaningful, and feasible to use.16 Both the 
durometer and the MSS proved reliable in the
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Table II. Spearman correlation coefficients 
between durometer scores and MSS
Total MSS vs DS PS vs DS
Observer 1, assessment 1 0.75 0.91
Observer 1, assessment 2 0.76 0.92
Observer 2, assessment 1 0.43 0.78
Observer 2, assessment 2 0.37 0.80
Observer 3, assessment 1 0.46 0.83
Observer 3, assessment 2 0.40 0.85
DS, Durometer score; PS, pliability component of MSS.
assessment of morphea. The interobserver vari­
ability of the durometer score was low, even lower 
than the interobserver variability of the MSS 
(0.5% vs 2.2%). Correlations between the total 
MSS and the durometer score were 0.5, which is 
not high. This is because in the MSS not only pli­
ability but also area of involvement is represented. 
This area of involvement, which accounts for half 
the total MSS, cannot be correlated with hardness 
measured by the durometer. If only the pliability 
scores in the MSS were correlated with the 
durometer scores, a correlation of 0.8 was found. 
In all analyses, the correlation coefficient never 
reached 1, which indicates that the highest durom­
eter scores are not always found in lesions with 
the highest score for pliability. An explanation 
might be that the durometer scores vary with the 
localization of the lesions on different body parts. 
The durometer values thus generally increase with 
clinical severity scores but do not always do so. 
This is in accord with the results found by 
Aghassi, Monoson, and Braverman10 and Falanga 
and Bucalo9 in systemic sclerosis. It is recom­
mended to use both methods simultaneously for 
the most accurate assessment of patients with 
morphea and for monitoring therapeutic effects in 
clinical trials.
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Single patch of hair at a denervated site in a patient with alopecia 
universalis
Deborah H. Atkin, MD,a Norman Levine, MD,a and Frank G. Walter, MDb Tucson, Arizona
Alopecia areata and its variants, alopecia total­
is and alopecia universalis, are diseases of 
unknown cause. We describe an unusual presenta­
tion of alopecia universalis that spared an area 
denervated during a lymph node biopsy.
CASE REPORT
A 36-year-old man with long-standing alopecia uni­
versalis was examined to evaluate recent nail changes. 
Nail pits and loss of lunulae had been present since 17 
years of age. He also reported loss of sensation in the 
right axilla after a lymphadenectomy also at 17 years of 
age, during which cutaneous branches of the intercos-
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Fig. 1* Patch of axillary hair adjacent to linear scar.
tobrachial nerve were severed. Alopecia universalis 
subsequently developed, with the exception of the right 
axilla.
Examination revealed complete hair loss except for
